Oryzon Genomics SA (ORYZF)

[pennystock_es]

Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum

BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, is scheduled to present at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum, being held February 23, 2016 at the New York Academy of Sciences in New York City.

Dr. Buesa’s presentation on the company’s strategy and development pipeline will take place on Tuesday, February 23rd 2016 at 14:55 pm EST. In addition, Dr. Buesa will also be a part of the Advances in Alzheimer’s Disease panel which will be held at 11:05 am EST.

Dr. Buesa commented, “We are excited to be presenting at the 1st Annual Neuroscience BioPartnering & Investment Forum. The presentation and the panel will provide us with an excellent opportunity to showcase Oryzon’s capability in developing potentially effective therapies through our epigenetics platform.”

The 1st Annual Neuroscience BioPartnering & Investment Forum will focus on key areas of neurodegenerative diseases and pain management. The event will feature special panels and company presentations. Key audiences at this event consist of analysts from the investment community, researchers and senior executives from pharma and biotech companies. The forum is an excellent platform to highlight investment and partnership opportunities.

About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015), is a clinical stage biopharmaceutical company considered the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon’s LSD1 program is currently covered by 19 patent families and has rendered two compounds in clinical trials . In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.


http://finance.yahoo.com/news/oryzon-genomics-announces-presentation-panel-130000351.html